Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 9/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18361889 | 0.88 | MTNR1A (0.43) | SSTR4SSTR1ALDH1A1SIGMAR1L3MBTL1 | |
| SCHEMBL358907 | 0.88 | MTNR1A (0.43) | SSTR4SSTR1ALDH1A1SIGMAR1L3MBTL1 | |
| SCHEMBL12162611 | 0.88 | MTNR1A (0.43) | SSTR4SSTR1ALDH1A1SIGMAR1L3MBTL1 | |
| SCHEMBL15337879 | 0.85 | SSTR4 (0.40) | SSTR4SSTR1ALDH1A1SIGMAR1 | |
| SCHEMBL25934538 | 0.85 | SSTR4 (0.40) | SSTR4SSTR1ALDH1A1SIGMAR1 | |
| SCHEMBL15337834 | 0.85 | SSTR4 (0.40) | SSTR4SSTR1ALDH1A1SIGMAR1 | |
| SCHEMBL10274562 | 0.81 | MTNR1A (0.49) | SSTR4SSTR1L3MBTL1 | |
| SCHEMBL20381540 | 0.81 | SSTR4 (0.42) | SSTR4SSTR1ALDH1A1DPP4 | |
| SCHEMBL2016900 | 0.80 | LMNA (0.48) | ALDH1A1DPP4L3MBTL1LMNAEPHX2 | |
| SCHEMBL12789759 | 0.79 | SSTR4 (0.42) | SSTR4SSTR1ALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368930-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368930-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | SSTR4 4780/4885SSTR1 4783/4885ALDH1A1 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.